Ratings Thermo Fisher Scientific Inc.

Equities

TMO

US8835561023

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:02 2024-12-09 pm EST			5-day change	1st Jan Change
537.23 ^USD	+1.49%		+1.43%	+1.21%

Dec. 09	RBC Trims Price Target on Thermo Fisher Scientific to $711 From $718, Keeps Outperform Rating	MT
Dec. 04	Thermo Fisher Scientific Insider Sold Shares Worth $10,624,559, According to a Recent SEC Filing	MT

Summary: Thermo Fisher Scientific Inc.

The company has a good ESG score relative to its sector, according to Refinitiv.

Highlights: Thermo Fisher Scientific Inc.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: Thermo Fisher Scientific Inc.

The company is in debt and has limited leeway for investment
With a 2024 P/E ratio at 32.51 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.

Ratings Chart: Thermo Fisher Scientific Inc.

Source: Surperformance

ESG chart: Thermo Fisher Scientific Inc.

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	THERMO FISHER SCIENTIFIC INC.				202B
	INTUITIVE SURGICAL, INC.				196B
	DANAHER CORPORATION				166B
	BOSTON SCIENTIFIC CORPORATION				133B
	SIEMENS HEALTHINEERS AG				60.84B
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.				43.72B
	EDWARDS LIFESCIENCES CORPORATION				42.19B
	AGILENT TECHNOLOGIES, INC.				40.09B
	GE HEALTHCARE TECHNOLOGIES INC.				37.12B
	RESMED, INC.				35.43B
	Average				95.69B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes